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Abstract
 
The administration of concanavalin A (Con A) induces a rapid severe injury of hepatocytes in
mice. Although the Con A–induced hepatitis is considered to be an experimental model of hu-
man autoimmune hepatitis, the precise cellular and molecular mechanisms that induce hepato-
cyte injury remain unclear. Here, we demonstrate that V
 
a
 
14 NKT cells are required and suffi-
cient for induction of this hepatitis. Moreover, interleukin (IL)-4 produced by Con A–activated
V
 
a
 
14 NKT cells is found to play a crucial role in disease development by augmenting the cyto-
toxic activity of V
 
a
 
14 NKT cells in an autocrine fashion. Indeed, short-term treatment with
IL-4 induces an increase in the expression of granzyme B and Fas ligand (L) in V
 
a
 
14 NKT
cells. Moreover, V
 
a
 
14 NKT cells from either perforin knock-out mice or FasL-mutant 
 
gld/gld
 
mice fail to induce hepatitis, and hence perforin–granzyme B and FasL appear to be effector
molecules in Con A–induced V
 
a
 
14 NKT cell–mediated hepatocyte injury.
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Introduction
 
The V
 
a
 
14 NKT cells are characterized by coexpression of
NK1.1, an NK cell marker, and an invariant antigen recep-
tor encoded by V
 
a
 
14J
 
a
 
281 gene segments associated with
highly skewed sets of V
 
b
 
s, mainly V
 
b
 
8.2 (V
 
a
 
14 NKT cell
receptor; references 1–7). Three lines of evidence suggest
that V
 
a
 
14 NKT cells are a novel lineage of lymphocytes: (a)
a targeted disruption of the invariant V
 
a
 
14J
 
a
 
281 gene
causes a selective loss of V
 
a
 
14 NKT cells, leaving other lym-
phocytes intact (8); (b) the transgenic expression of the in-
variant NKT antigen receptor (V
 
a
 
14/V
 
b
 
8.2) genes in re-
combination activating gene (RAG)
 
1
 
 knock-out (KO)
mice results in the exclusive development of V
 
a
 
14 NKT
cells but not other lymphocytes, including T cells (9); and
(c) V
 
a
 
14 NKT cells develop at an early stage of embryo-
genesis before thymus formation (10).
It has been reported that V
 
a
 
14 NKT cells specifically
recognize 
 
a
 
-galactosylceramide (
 
a
 
-GalCer; references 9 and
11) or parasite (malaria or trypanosoma) glycosylphosphati-
dylinositols (12), both of which are presented by a mono-
morphic class Ib molecule, CD1d. Upon activation with
 
a
 
-GalCer, V
 
a
 
14 NKT cells exert a perforin-dependent an-
titumor cytotoxicity and prevent tumor metastasis in the
liver or lung (11). Interestingly, the activated V
 
a
 
14 NKT
cells produce both IL-4 and IFN-
 
g 
 
(9, 13, 14). Thus, it is
important to know whether V
 
a
 
14 NKT cells behave like
either Th1 or Th2 cells, whose dysfunction or imbalance
may affect immune responses and lead to disease develop-
ment. In fact, IFN-
 
g
 
 but not IL-4 produced by activated
V
 
a
 
14 NKT cells produces dominant functional effects on
helper T cell differentiation by suppressing Th2 develop-
ment and IgE antibody responses (15). We and others have
demonstrated that a selective loss or dysfunction in V
 
a
 
14
NKT cells is tightly associated with autoimmune disease
development in 
 
lpr/lpr
 
 and nonobese diabetic mice (16–18).
In fact, the transfer of the invariant V
 
a
 
14 gene into non-
obese diabetic mice prevents disease development (19). In
addition, V
 
a
 
14 NKT cells appear to play a critical role in
liver injury after 
 
Salmonella
 
 infection (20). Similarly, human
NKT cells have been reported to play significant roles in
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various human autoimmune diseases, including autoim-
mune diabetes (21) and systemic sclerosis (22). These results
suggest that V
 
a
 
14 NKT cells play a crucial role in various
immune responses, including antitumor immunity, allergic
reaction, and the development of autoimmune diseases.
Con A–induced hepatitis is considered to be an experi-
mental murine model of human autoimmune hepatitis
(23). The hepatocyte injury is associated with lymphocyte
infiltration, suggesting the involvement of immune reac-
tions. In fact, this hepatitis is not observed in athymic nude
mice or SCID mice (23), both of which lack T cells. Fur-
thermore, in vivo treatment with anti–Thy-1 or anti-CD4
mAbs or with FK506 or cyclosporin A prevents the hepatitis,
suggesting a requirement for CD4
 
1
 
 T cells or TCR-medi-
ated signals for Con A–induced hepatitis (23). In addition,
immunohistological analyses confirm the infiltration of CD4
 
1
 
T cells in the portal area of the liver (24).
Recently, Toyabe et al. reported the involvement of
NK1.1
 
1
 
 T cells in Con A–induced hepatitis (25). When
NK1.1
 
1
 
 cells are depleted by the administration of anti-NK1.1
antibody in vivo, the mice become resistant to the hepatitis,
suggesting that NK1.1
 
1
 
 cells are indispensable (25). How-
ever, hepatitis does not develop in 
 
b
 
2 microglobulin KO
mice, in which the development of V
 
a
 
14 NKT cells is se-
verely perturbed, despite the normal development of NK
cells (25). Thus, it is conceivable that V
 
a
 
14 NKT cells
rather than NK cells are involved in Con A–induced hepa-
titis, although no direct experiments addressing this issue
have been reported.
The hepatic injury seems to be induced by several different
mechanisms, such as those involving the Fas–Fas ligand (L)
system (26–28), perforin–granzyme system (29), and IFN-
 
g
 
–
(26, 30) and/or TNF-
 
a
 
–mediated cytotoxicity (24, 25,
31–34). However, the results are controversial, and the precise
molecular requirements for the induction of hepatocyte in-
jury by Con A are still largely unknown. In this report, we
investigate the role of V
 
a
 
14 NKT cells in Con A–induced
hepatitis using two strains of gene-manipulated mice estab-
lished in our laboratory: (a) V
 
a
 
14 NKT KO mice, where
only the V
 
a
 
14 NKT cells are deficient and other lymphoid
populations, such as T cells, B cells, and NK cells, remain in-
tact (8); and (b) V
 
a
 
14 NKT (V
 
a
 
14 transgenic (Tg)/V
 
b
 
8Tg/
RAG KO) mice that have only V
 
a
 
14 NKT cells and not T
cells, B cells, or NK cells (9). Our results suggest that V
 
a
 
14
NKT cells are required and sufficient for the development of
Con A–induced hepatitis. In addition, IL-4 produced by Con
A–activated V
 
a
 
14 NKT cells appears to upregulate FasL and
granzyme B expression in V
 
a
 
14 NKT cells in an autocrine
fashion and is indispensable for the induction of the hepatitis.
 
Materials and Methods
 
Mice.
 
8–10-wk-old male C57BL/6 (B6) mice and B6-
 
gld/gld
 
mice were purchased from Japan SLC Inc. V
 
a
 
14 NKT KO mice
were established by specific deletion of the J
 
a
 
281 gene segment
with homologous recombination and aggregation chimera tech-
niques (8) and were backcrossed nine times with B6 mice. V
 
a
 
14
NKT (V
 
a
 
14Tg/V
 
b
 
8.2Tg/RAG KO) mice were established and
 
backcrossed four times with B6 mice (9). IL-4 KO mice were
originally generated by Kopf et al. (35). IFN-
 
g
 
 KO (26) and per-
forin KO mice (36) were provided by Dr. Y. Iwakura (Institute
of Medical Science, University of Tokyo, Tokyo, Japan). RAG
KO mice were provided by Dr. P. Mombaerts (Massachusetts In-
stitute for Technology, Boston, MA; reference 37). All mice used
were maintained under specific pathogen–free conditions in our
animal facility. Animal care was in accordance with the guidelines
of Chiba University.
 
Preparation of Liver Mononuclear Cells.
 
Liver mononuclear cells
were isolated as previously described (38, 39). In brief, the liver
was pressed through stainless steel mesh (no. 200) and suspended
in PBS. After washing once, the cells were resuspended in 33%
Percoll solution containing heparin (100 U/ml), centrifuged at
2,000 rpm for 15 min at room temperature, and subjected to
PCR and flow cytometry analyses.
 
Enrichment of NK1.1
 
1
 
 Cells by MACS.
 
Spleen cells were stained
with FITC-conjugated anti-NK1.1 mAb and then cultivated with
anti-FITC MicroBeads (no. 487-01; Miltenyi Biotec Inc.) for
15 min at 4
 
8
 
C. NK1.1
 
1
 
 cells were enriched by magnetic cell sorting
according to the manufacturer’s protocol (Miltenyi Biotec Inc.).
About 45% of the MACS-purified cells were TCR-
 
b
 
1 
 
NK1.1
 
1
 
NKT cells. Most other populations were NK cells, which produce
neither IL-4 nor IFN-
 
g
 
 upon Con A stimulation (see Fig. 4 A).
 
Preparation of V
 
a
 
14 NKT and T Cell Lines.
 
Spleen cells (4 
 
3
 
10
 
4
 
 per well) from V
 
a
 
14 NKT mice or MACS-enriched
NK1.1
 
1
 
 cells from B6, IL-4 KO, or IFN-
 
g
 
 KO mice were cul-
tured in anti-CD3 mAb (2C11; 100 
 
m
 
g/ml)–coated 96-well plates
(Falcon 3077) in the presence of 50 U/ml of recombinant mouse
IL-2 for 3 d and further cultured for 2 d without anti-CD3 stim-
ulation. More than 90% of the cultured cells from V
 
a
 
14 NKT
mice and 
 
z
 
50% of the cultured cells from B6, IL-4 KO, or INF-
 
g
 
KO mice were V
 
a
 
14 NKT cells. T cell lines were also estab-
lished under the same protocol as above with spleen T cells from
V
 
a
 
14 NKT KO mice.
 
Flow Cytometric Analysis.
 
Spleen cells (10
 
6
 
) were incubated
with anti-FcR (2.4G2; PharMingen), stained with mAbs (0.5
 
m
 
g/ml) at 4
 
8
 
C for 30 min, and analyzed by EPICS XL-MCL
(Beckman Coulter). FITC-conjugated anti–TCR-
 
b
 
 (H57-597;
PharMingen) and PE-conjugated anti-NK1.1 (PK136; PharMin-
gen) mAbs were used to identify the NKT cell population. Anti–
IL-4R
 
a
 
 (Genzyme Corp.), anti–common 
 
g
 
 chain (PharMingen),
and biotin-conjugated goat anti–rat Ig antibodies were used to
stain the IL-4R complex. For IFN-
 
g
 
R
 
a
 
, biotinylated anti–IFN-
 
g
 
Ra (PharMingen) was used. Dead cells were excluded by for-
ward scatter, side scatter, and propidium iodide gating.
PCR.  To detect the rearranged Va14Ja281 genes of mi-
grated Va14 NKT cells, genomic PCR was carried out on liver
DNA from Va14 NKT KO mice after transfer of Va14 NKT
cells by the method described in reference 40 using the following
primers: 59-CCGAATTCCCAAGTGGAGCAGAGTCCT-39 and
59-CCAAAATGCCTCCCTAA-39. Reverse transcriptase–PCR
was carried out on 1 mg of total RNA obtained from cultured
Va14 NKT cells as described (10) using the following primers:
b-actin, 59-GAGAGGGAAATCGTGCGTGA-39 and 59-ACAT-
CTGCTGGAAGGTGGAC-39; granzyme B, 59-GCCCACA-
ACATCAAAGAACAG-39 and 59-AACCAGCCACATAGCA-
CACAT-39; FasL, 59-CTGGAATGGGAAGACACATA-39 and
59-AAAGGTCTTAGATTCCTCAA-39; and TNF-a, 59-ATG-
AGCACAGAAAGCATGATC-39 and 59-TACAGGCTTGTC-
ACTCGAATT-39.
Competitive PCR. Competitor DNAs were constructed by
PCR using a competitor DNA construction kit following the107 Kaneko et al.
manufacturer’s instructions (Takara Shuzo). A mixture of the
cDNA and defined copy numbers of competitors was subjected
to PCR amplification (40) using the primers described above.
The ratio of the longer competitive product to the shorter target
DNA product was used to estimate the amounts of target DNAs
(490 vs. 454 bp for b-actin, 242 vs. 216 bp for granzyme B, 390 vs.
346 bp for FasL, and 342 vs. 276 bp for TNF-a).
Administration of Con A and Measurement of Serum Transaminase
Activities. Con A was purchased from Sigma Chemical Co. (cat.
C0412). Either 0.5 mg (z25 mg/kg) or 0.75 mg (z37.5 mg/kg)
of Con A was dissolved in 200 ml of pyrogen-free PBS and in-
jected intravenously into mice. Serum activities of alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST) were
measured by Lippi-Guidi’s method as described (Iatrozyme TA-
LQ; Dia-Iatron; reference 41).
Adoptive Cell Transfer. Va14 NKT KO mice received spleen
cells (2 3 107) from Va14 NKT mice or splenic Va14 NKT cells
(5 3 106) isolated by MACS from B6, IL-4 KO, IFN-g KO, gld/gld,
or perforin KO mice. The Va14 NKT cell line (2 3 106) was
also used for cell transfer. 1 h after cell transfer, the mice were in-
jected intravenously with Con A (0.5 mg).
Measurement of Cytokines in Culture Supernatants. Spleen cells
(106 per well) from B6, Va14 NKT KO, or Va14 NKT mice or
the Va14 NKT cell line and conventional T cell line were stim-
ulated with Con A (10 mg/ml) for 24 h in 200-ml cultures. The
amounts of IL-4 and IFN-g in the culture supernatants were as-
sayed using ELISA kits (EN-2601-80 and EN-2604-50; Endo-
gen, Inc.) according to the manufacturer’s protocol.
Histological Examination. The livers from individual mice
were fixed in 10% formalin, embedded in paraffin, sectioned, and
stained with hematoxylin and eosin for histological examination.
Specimens were examined under a light microscope.
51Cr-Release Cytotoxic Assay. The cytotoxic activity of Va14
NKT cells upon activation with either IL-4 (100 U/ml; R & D
Systems, Inc.) or IFN-g (100 U/ml) for 8 h at 378C was assayed
by 4-h 51Cr-release cytotoxic assay on the TLR2 hepatocyte cell
line (RIKEN Cell Bank) as described (42). The cells were har-
vested and seeded at the indicated E/T ratios (see Fig. 6 B).
Results
Requirement of Va14 NKT Cells for Con A–induced Hepa-
titis. We investigated the role of Va14 NKT cells in the
development of Con A–induced hepatitis using Va14 NKT
KO mice lacking only Va14 NKT cells. B6, Va14 NKT
KO, and RAG KO mice were injected intravenously with
Con A, and the induction of hepatitis was evaluated by
measuring the activities of two transaminases (ALT and
AST) in the serum 12, 24, 36, 48, and 72 h after Con A
treatment. As shown in Fig. 1 (A and B) the activities of
both transaminases in B6 mice increased rapidly, reaching
their peak values at 12 h. In contrast, no increase in the lev-
els of either ALT or AST was detected in Va14 NKT KO
mice. These results strongly indicate that Va14 NKT cells
are required for hepatocyte injury mediated by Con A
(Con A–induced hepatitis). In RAG KO mice, where only
NK cells and no other lymphoid lineage cells develop, no
increase in the level of either transaminase was detected,
suggesting that NK cells are not essential.
Restoration of Con A–induced Hepatitis by Va14 NKT Cell
Transfer. The requirement of Va14 NKT cells for the de-
velopment of hepatitis was further evaluated by experi-
ments involving the adoptive transfer of Va14 NKT cells
into Va14 NKT KO mice. 9 h after the intrasplenic injec-
tion of freshly isolated spleen cells (2 3 107) from Va14
NKT mice, considerable numbers of transferred Va14 NKT
cells had migrated into the livers of recipient Va14 NKT
KO mice, as evidenced by the increased percentages of
TCR-b1NK1.11 NKT cells (Fig. 2 A) and detectable
amounts of rearranged Va14Ja281 genes in the liver as as-
sessed by genomic PCR (Fig. 2 B).
As shown in Fig. 2 (C and D) the serum levels of the he-
patic transaminases, ALT and AST, were significantly in-
creased in Va14 NKT KO mice receiving either freshly
isolated Va14 NKT cells (Fig. 2 C) or Va14 NKT cell line
(Fig. 2 D) in a dose-dependent manner. The intrasplenic
injection of splenic Va14 NKT cells (2 3 107) or Va14
NKT cell line (2 3 106) resulted in almost full recovery. It
was noted that neither intraperitoneal nor intravenous in-
jection of Va14 NKT cells induced any detectable eleva-
tion in the activities of these transaminases (data not
shown). Thus, the intrasplenic route appears to be critical
for the successful migration of Va14 NKT cells into the re-
cipient liver. Collectively, Va14 NKT cells, together with
the administration of Con A, are essential for the induction
of Con A–induced hepatitis.
An Indispensable Role of Va14 NKT Cells in the Develop-
ment of Con A–induced Hepatitis. It is of interest whether
Va14 NKT cells are the final effector cells or the inducer
cells in Con A–induced hepatitis. To address this question,
we used Va14 NKT mice that have only Va14 NKT cells
and no T, B, or NK cells. A dramatic elevation of serum
Figure 1. Elevation of serum trans-
aminase activities after intravenous in-
jection of Con A. Serum transaminase
levels in B6 wild-type (d), Va14 NKT
KO (h), and RAG KO (n) mice were
assessed at different times after Con A
(0.5 mg) administration. Three mice
were used in each group. The mean
transaminase activities (Karmen units per
liter [K.U./l]) of ALT (A) and AST (B)
of triplicate samples with standard errors
are depicted.108 Role of IL-4 in Con A–induced Hepatitis
transaminases was observed in Va14 NKT mice, and all
mice died within 24 h when 0.75 mg of Con A was used
(Fig. 3). The transaminase elevation was not reproducibly
observed in Va14 NKT mice receiving a regular dose of
Con A (0.5 mg; data not shown). This observation suggests
that other cell components, such as T cells, are also in-
volved, and that the hepatitis is induced more efficiently in
wild-type than in Va14 NKT mice. Thus, we used 0.75
mg of Con A in the experiments with Va14 NKT mice.
We carried out histological examinations of the liver 8 h
after the administration of 0.75 mg of Con A (Fig. 3 B). In
B6 mice, a severe bridging necrosis was observed in the
area between the central veins and the portal tracts (3200;
arrow). In addition, photographs at higher magnification
(400) revealed the infiltration of mononuclear cells (arrow-
heads) and Kupffer cells within sinusoids adjacent to the
degenerated hepatocytes. Massive red blood cells were also
observed in the sinusoidal area. Similar histological findings
were observed in the livers of Va14 NKT mice. In con-
trast, no significant histological changes were observed in
Va14 NKT KO mice. Essentially similar histological find-
ings were observed in B6 mice receiving 0.5 mg of Con A
(data not shown). These results indicate that Con A–induced
hepatitis is evoked by Va14 NKT cells even in the absence
of conventional T, B, and NK cells.
Preferential Production of IL-4 by Con A–activated Va14
NKT Cells. To address the molecular mechanisms under-
lying Va14 NKT cell–mediated hepatocyte injury, we first
assessed the production of cytokines from Va14 NKT cells
stimulated with Con A. This is because Va14 NKT cells
are known to produce both IL-4 and IFN-g very rapidly
when they are stimulated with anti-CD3 mAb (13, 14) or
the ligand a-GalCer (9). Spleen cells from B6, Va14 NKT
KO, Va14 NKT, and RAG KO mice were stimulated in
vitro with 10 mg/ml of Con A, and the amounts of IL-4
and IFN-g produced in the culture supernatants were as-
sessed by ELISA. As shown in Fig. 4 A, spleen cells from
Va14 NKT mice produced levels of IL-4 several times
higher than those produced by B6 or Va14 NKT KO
mice. In addition, unexpectedly low amounts of IFN-g
were produced after stimulation with Con A. In RAG KO
mice bearing only NK cells, as expected, no IL-4 or IFN-g
was produced, suggesting that NK cells are not the produc-
ers of these cytokines upon Con A stimulation (Fig. 4 A).
These results suggest that Va14 NKT cells produce large
amounts of IL-4 upon Con A stimulation. Similar results
were obtained using the Va14 NKT cell line (Fig. 4 B).
Requirement of IL-4 but not IFN-g Produced by Va14 NKT
Cells for the Development of Con A–induced Hepatitis. In the
next experiments, the involvement of IL-4 and IFN-g pro-
duced by Va14 NKT cells in Con A–induced hepatitis was
examined in vivo. Va14 NKT cells were enriched from
spleens of B6, IL-4 KO, and IFN-g KO mice by MACS
using anti-NK1.1 mAb. The cells were adoptively trans-
ferred into Va14 NKT KO mice (Fig. 5 A). Similarly, the
Va14 NKT cell line was transferred into Va14 NKT KO
mice (Fig. 5 B). The mice were then injected intravenously
with Con A, and ALT and AST transaminase activities
were measured 8 h later. As shown in Fig. 5, Va14 NKT
cells derived from IL-4 KO mice did not restore hepatitis,
whereas those from IFN-g KO mice elicited a significant
elevation in serum transaminase activities to levels equiva-
lent to those induced by Va14 NKT cells from B6 mice.
Va14 NKT cells from IL-4 KO mice produced levels of
Figure 2. Restoration of Con A–induced hepatitis by Va14 NKT cells in Va14 NKT KO mice. (A) TCR-b/NK1.1 profiles of liver mononuclear
cells of Va14 NKT KO mice 9 h after adoptive transfer of 2 3 107 spleen cells from Va14 NKT mice are shown. The percentages of cells present in
each area are shown in each panel. (B) The rearranged Va14Ja281 gene was assessed by genomic PCR with specific primers detecting Va14Ja281.
Va14 NKT KO mice were intrasplenically injected with the indicated numbers of freshly prepared whole spleen cells from Va14 NKT mice (C) or
Va14 NKT cell line established from spleen cells (spl.) of Va14 NKT mice (D). 1 h after cell transfer, the mice were administered Con A (0.5 mg; Stim.)
intravenously. The serum ALT and AST activities were measured 8 h after Con A injection. Three mice were used in each group, and the serum samples
were analyzed individually. The mean values of triplicate samples with standard errors are shown.109 Kaneko et al.
IFN-g equivalent to those of B6 mice (data not shown).
These results clearly indicate that IL-4 but not IFN-g pro-
duced by Va14 NKT cells is required for the development
of Con A–induced hepatitis.
Enhancement of Va14 NKT Cell–mediated Cytotoxicity
upon Stimulation with IL-4. The next experiments were
designed to clarify the effector mechanism of IL-4 in the
development of Con-A–induced hepatitis. First, the effect
of IL-4 on Va14 NKT cell–mediated cytotoxicity was
assessed. Significant levels of IL-4R (both a chain and
common g chain) as well as IFN-gR were expressed on
the freshly isolated Va14 NKT cells (Fig. 6 A). Conse-
quently, freshly prepared Va14 NKT cells were incu-
bated with 100 U/ml of recombinant IL-4 for 8 h in vitro.
The effect of IFN-g was also examined. To our surprise,
the cytotoxic activity of Va14 NKT cells against the TLR2
hepatocyte cell line was significantly enhanced when Va14
NKT cells were treated with IL-4 but not with IFN-g (Fig.
6 B). Similar results were obtained in experiments using
other target cells, such as YAC-1 (data not shown). Conse-
quently, we examined the expression of granzyme B, FasL,
and TNF-a in IL-4–stimulated Va14 NKT cells by compet-
itive PCR assay. The FasL and granzyme B transcripts but
not TNF-a transcripts in Va14 NKT cells were significantly
enhanced (z10-fold) by treatment with IL-4 (Fig. 6 C).
The role of these molecules produced or expressed by
Va14 NKT cells in vivo was assessed by cell transfer exper-
iments. As shown in Fig. 7, Va14 NKT cells isolated from
FasL-mutant gld/gld mice or perforin KO mice failed to re-
store the induction of hepatitis (Fig. 7). Thus, both per-
forin and FasL are essential for the development of this
hepatitis. Taken with the results shown in Fig. 6, it is most
likely that the Con A–stimulated Va14 NKT cells release
IL-4, which in turn acts on Va14 NKT cells to enhance
their cytotoxic activity by upregulating the expressions of
granzyme B and FasL.
Figure 3. Development of Con A–induced
hepatitis in Va14 NKT mice. (A) Serum
transaminase levels in B6 and Va14 NKT
mice 12 h after Con A administration
(0.75 mg). All mice died within 24 h (†).
The mean values of three samples with
standard errors are shown. (B) Light mi-
crographs of the liver with hematoxylin
and eosin staining (3200 and 3400) are
shown. The indicated mice were treated
with 0.75 mg of Con A and killed 8 h
later. Arrows indicate massive necrosis ob-
served in the liver; arrowheads indicate
mononuclear cell infiltration. WT, wild-
type.110 Role of IL-4 in Con A–induced Hepatitis
Discussion
It has been suggested that CD41 T cells (23, 24) and
NK1.11 T cells (25) are involved in the development of Con
A–induced hepatitis, although the precise cellular and molec-
ular requirements have not been clarified. We demonstrate
here that Va14 NKT cells, a novel lymphocyte lineage, are
required and sufficient for the development of hepatitis.
Va14 NKT mice possessing only Va14 NKT cells exhibited
a dramatic increase in serum transaminase levels after injection
of Con A, and all mice died within 24 h (Fig. 3 A). In sharp
contrast, Va14 NKT KO mice lacking only Va14 NKT cells
did not develop hepatocyte injury (Fig. 1) or mononuclear
cell infiltration into the liver (Fig. 3 B). Thus, Va14 NKT
cells are able to function as effector cells to develop Con
A–induced hepatitis in the absence of conventional T cells.
In this study, the involvement of CD41 T cells in the
disease development reported by several investigators (23–34)
is not formally addressed. However, T cells seem to be
clearly involved in the development of this hepatitis, be-
cause the hepatitis occurs more efficiently in the presence
of both CD41 T cells and Va14 NKT cells than Va14
NKT cells alone. In our experimental system, Va14 NKT
mice lacking T cells require 0.75 mg of Con A for the re-
producible induction of hepatitis, whereas 0.5 mg of Con
A is sufficient in wild-type mice (Fig. 1 and Fig. 3 A).
It is interesting to note that the level of transaminase ele-
vation depends on the number of Va14 NKT cells trans-
ferred (Fig. 2 C). The hepatitis induction was restored by
transfer of freshly isolated Va14 NKT cells or Va14 NKT
cell lines in a dose-dependent fashion. These findings are
also confirmed in physiological situations. For example, SJL/J
mice are known to have significantly lower numbers of
NKT (TCR-b1IL-2Rb1) cells compared with other con-
genic mice (43, 44) and indeed were relatively resistant to
Con A–induced hepatitis (data not shown). In addition,
young mice, such as 2-wk-old B6 mice, had a few NKT
cells (z30% of adult levels; reference 45) and were consider-
ably resistant to Con A (data not shown). Collectively, in
normal wild-type mice, the administration of Con A appears
to induce a destructive immune response leading to hepato-
cyte injury, which is probably initiated and mediated by
Va14 NKT cells and exacerbated by conventional T cells.
More interestingly, IL-4 produced by Con A–stimulated
Va14 NKT cells appears to play an indispensable role in
disease development by enhancing the cytotoxic activity of
Figure 5. Requirement of IL-4 produced
by Va14 NKT cells for Con A–induced
hepatitis. (A) MACS-sorted NK1.11 spleen
cells (107) from B6, IL-4 KO, or IFN-g KO
mice were transferred intrasplenically into
Va14 NKT KO mice. 1 h later, the mice
were injected with Con A (0.5 mg). The
serum activities of ALT and AST were as-
sessed 8 h after Con A injection. (B) Induc-
tion of Con A–induced hepatitis by adop-
tive transfer of cells from the Va14 NKT
cell line (2 3 106). Three mice were used in
each group. The mean values in triplicate
with standard errors are shown.
Figure 4. Production of IL-4 and IFN-g from Con
A–activated Va14 NKT cells. Whole spleen cells
from B6, Va14 NKT KO, Va14 NKT, and RAG
KO mice (A) or the Va14 NKT cell line and conven-
tional T cell line (B) were stimulated in vitro with
Con A (10 mg/ml). 24 h later, the amounts of IL-4 or
IFN-g in the culture supernatants were measured by
ELISA. Mean values in triplicate samples with stan-
dard deviations are shown. n.d., not detectable.111 Kaneko et al.
Va14 NKT cells. In fact, freshly isolated Va14 NKT cells
express significant levels of IL-4R (IL-4Ra and common g
chains) on their cell surfaces (Fig. 6 A), and the short-term
treatment of Va14 NKT cells with IL-4 results in a dra-
matic enhancement of cytotoxic activity against various tar-
get cells, including a hepatocyte cell line (Fig. 6 B). The
enhanced cytotoxic activity induced by IL-4 accompanied
increases in the levels of granzyme B and FasL mRNAs
(Fig. 6 C). These results are in good agreement with find-
ings that Con A–induced hepatitis is significantly inhibited
in IL-4 KO mice (data not shown) or by pretreatment with
anti–IL-4 mAb (25) and that Va14 NKT cells from IL-4
KO mice do not initiate Con A–induced hepatitis (Fig. 5).
Thus, it is most likely that the IL-4 produced by Con
A–activated Va14 NKT cells acts on Va14 NKT cells in
an autocrine fashion and induces upregulation of granzyme
B and FasL transcripts, resulting in an enhancement of
Va14 NKT cell–mediated cytotoxicity.
Several cytotoxic effector molecules are considered to be
involved in the development of Con A–induced hepatitis.
First is the perforin–granzyme system that is known to in-
duce hepatocyte injury (29). Indeed, perforin KO mice
(29) and Va14 NKT cells from perforin KO mice fail to
develop Con A–induced hepatitis (Fig. 7), suggesting that
the perforin–granzyme system is essential for the induction
of Va14 NKT cell–mediated hepatitis.
Although the involvement of the Fas–FasL system in the
induction of Con A–induced hepatitis is controversial (26–29,
34), the system is likely to be one of the effector mecha-
nisms for hepatocyte injury, particularly for Va14 NKT
cell–mediated hepatocyte injury. In fact, this hepatitis has
been reported to be significantly milder in Fas-mutant lpr/lpr
mice (26, 28), and it is completely abrogated in gld/gld
mice in which FasL is defective (27, 28) or in mice pre-
treated with anti-FasL antibody (28). It is also well known
that the stimulation of Fas on hepatocytes by anti-Fas anti-
body causes severe damage to hepatocytes by apoptotic cell
death (46). In addition, normal hepatocytes express a signif-
icant amount of Fas (46), and the expression level of Fas
mRNA in hepatocytes is increased upon Con A stimula-
tion (26). As shown in Fig. 6 C, levels of FasL mRNA are
significantly upregulated by IL-4 treatment. Thus, it is con-
ceivable that a direct interaction between IL-4–stimulated
Va14 NKT cells expressing high levels of FasL and Con
A–stimulated hepatocytes with an augmented expression of
Fas results in the induction of apoptotic cell death in hepa-
tocytes. Moreover, as demonstrated in Fig. 7, cell transfer
of Va14 NKT cells obtained from FasL-mutant gld/gld mice
Figure 7. Requirement of FasL expression and
perforin production from Va14 NKT cells for
Con A–induced hepatitis. MACS-sorted NK1.11
spleen cells (107) from B6, B6-gld/gld, or perforin
KO mice were transferred intrasplenically into
Va14 NKT KO mice. 1 h later, the mice were
injected with Con A (0.5 mg). 8 h later, the se-
rum activities of ALT and AST were assessed.
The mean values of triplicate samples with stan-
dard errors are shown.
Figure 6. Augmentation of the
cytotoxic activity of Va14 NKT
cells by short-term incubation with
IL-4 in vitro. (A) Flow cytometric
analysis of the expression of IL-4 and
IFN-gRs on freshly isolated Va14
NKT cells. (B) Spleen cells from
Va14 NKT mice were cultured for
8 h in the presence of 100 U/ml of
IL-4 or 100 U/ml of IFN-g. The
cells were washed extensively and
subjected to the standard 51Cr-
release cytotoxic assay in triplicate
on target TLR2 liver cells. (C) Aug-
mented expression of mRNAs of
granzyme B and FasL in Va14 NKT
cells upon stimulation with IL-4.112 Role of IL-4 in Con A–induced Hepatitis
fails to restore the induction of Con A–induced hepatitis.
This result indicates that the Fas–FasL system is crucial for
Va14 NKT cell–mediated hepatocyte injury.
In addition to the contribution of perforin and FasL as ef-
fector molecules in Va14 NKT cell–mediated hepatitis,
TNF-a and IFN-g produced by non-NKT cells such as
macrophages and CD41 T cells, respectively, are reported to
play crucial roles in the development of Con A–induced
hepatitis. It is demonstrated that mice pretreated with anti–
mouse TNF-a antiserum (31) or TNF-a inhibitor (TNF
binding protein; reference 34) or mice deficient for TNFR1
and TNFR2 are resistant to Con A–induced hepatitis (33)
and that the enhanced TNF-a production after Con A stim-
ulation appears to be produced mainly by macrophages in
the liver (32). In fact, TNF-a mRNA expression in Va14
NKT cells is unchanged even after IL-4 treatment (Fig. 6 C).
IFN-g also seems to be important for the development
of Con A–induced hepatitis, because mice pretreated with
anti–IFN-g antiserum (30) or IFN-g–deficient mice (26) are
resistant to Con A–induced hepatitis. For IFN-g production,
CD41 T cells seem to be responsible, because Con A–acti-
vated T cells produce large amounts of IFN-g, and Va14
NKT cells produce a little (Fig. 4). It is likely that IFN-g
directly acts on hepatocytes and induces hepatocyte injury,
as hepatocytes express IFN-gR on the cell surface (47). It is
also interesting to note that IFN-g upregulates TNFRs on
the hepatocyte cell surface (48, 49). This could be the reason
for the enhancing effects of IFN-g on TNF-induced apop-
tosis (30). Thus, synergistic effects of IFN-g and TNF-a
produced by CD41 T cells and macrophages may acceler-
ate apoptosis in hepatocytes.
Con A–induced hepatitis is thought to be a model of
immunologically induced hepatocyte injury, and its histo-
logical features resemble those of viral or drug-induced acute
hepatitis in humans (50, 51). The function of Va24Vb11
NKT cells in humans, a counterpart of mouse Va14 NKT
cells, is highly conserved, e.g., sharing ligand specificity and
CD1d restriction (52–54); these cells also possess potent cy-
totoxic activity against a wide variety of tumor cells (55).
Thus, it is easy to speculate that Va24Vb11 NKT cells play
a critical role in certain types of acute hepatitis in humans.
More recently, it has been demonstrated that Va14 NKT
cells are activated by parasite glycosylphosphatidylinositol
(12) or bacterial LPS (56), indicating their physiological roles
in the immune responses to microorganisms. This suggests
that murine Va14 NKT cells or human Va24 NKT cells are
involved in the development of various diseases or regulation
of immune responses after microbial infections.
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